Depression, Chronic Fatigue Syndrome, and Fibromyalgia

References

• Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: A comprehensive approach to its definition and study. Ann Intern Med 1994; 121:953–959.
   PubMed Web of Science ®Google Scholar
• Holmes GP, Kaplan JE, Gantz NM, et al. Chronic fatigue syndrome: A working case definition. Ann Intern Med 1988; 108:387–389.
   PubMed Web of Science ®Google Scholar
• Jenkins R, Mowbray J, Eds. Post-Viral Fatigue Syndrome. Chichester, Eng-land: Wiley; 1991.
   Google Scholar
• Straus SE, Dale JK, Tobi M, Lawley T, Preble O, Blaese RM, Hallahan C, Henle W. Acyclovir treatment of chronic fatigue syndrome. Lack of efficacy in a placebo-controlled trial. N Engl J Med 1988; 319:1692–1698.
   Google Scholar
• Komaroff AL, Fagioli LR, Geiger AM, Doolittle TH, Lee J, Kornish RJ, Gleit MA, Guerriero RT. An examination of the working case definition of chronic fa-tigue syndrome. Am J Med 1996; 100:56–63.
   PubMed Web of Science ®Google Scholar
• Bombardier CH, Buchwald DR. Outcome and prognosis of patients with chro-nic fatigue vs. chronic fatigue syndrome. Arch Intern Med 1995; 155:2105–2110.
   PubMed Web of Science ®Google Scholar
• Goldenberg DL. Fibromyalgia and its relation to chronic fatigue syndrome, vi-ral illness, and immune abnormalities. J Rheumatol 1989; 16:S91–S93.
   Google Scholar
• Goldenberg DL. Fibromyalgia syndrome. JAMA 1987; 257:2782–2787.
   PubMed Web of Science ®Google Scholar
• Komaroff AL. A 56 year old woman with chronic fatigue syndrome. JAMA 1997; 278:1179–1185.
   PubMed Web of Science ®Google Scholar
• Komaroff AL, Goldenberg D. The chronic fatigue syndrome: Definition, cur-rent studies, and lessons for fibromyalgia research. J Rheumatol Supplement 1989; 19:23–27.
   PubMedGoogle Scholar
• Komaroff AL. Clinical presentation of chronic fatigue syndrome. CIBA Foun-dation Symposium 1993; 173:43–54; discussion 54-61.
   PubMedGoogle Scholar
• Potaznick W, Kozol N. Ocular manifestations of chronic fatigue and immune dysfunction syndrome. Optom Vis Sci 1992; 69:811–814.
   PubMed Web of Science ®Google Scholar
• Caffery BE, Josephson JE, Samek Mt. The ocular signs and symptoms of chronic fatigue syndrome. J Am Optom Assoc 1994; 65:187–191.
   PubMedGoogle Scholar
• Scott LV, Teh J, Reznek R, Martin A, Sohaib A, Dinan G. Small adrenal glands in chronic fatigue syndrome: A preliminary computer tomography study. Psycho-neuroendocrinology 1999; 24:759–768.
   PubMed Web of Science ®Google Scholar
• Gillin JC. Sleep studies in affective illness. Psychiatric Annals 1983; 13:367–384.
   Web of Science ®Google Scholar
• Moldofsky H, Saskin P, Pue FA. Sleep and symptoms in fibrositis syndrome af-ter a febrile illness. J Rheumatol 1988; 15:1701–1704.
   Google Scholar
• Whelton CL, Salit I, Modofsky H. Sleep, Epstein-Barr virus infection, musculoskeletal pain, and depressive symptoms in chronic fatigue syndrome. J Rheumatol 1992; 19:939–943.
   Google Scholar
• Carette S, Oakson G, Guimont C, Steriade M. Sleep encephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum 1995; 38:1211–1217.
   PubMed Web of Science ®Google Scholar
• Buchwald D, Pascualy R, Bombardier C, et al. Sleep disorders in patients with chronic fatigue. Clin Infect Dis 1994; 18\(suppl 1):568–S72.
   Google Scholar
• Montague TJ, Marrie TJ, Klassen GA, Bewick DJ, Horacek BM. Cardiac func-tion at rest and with exercise in chronic fatigue syndrome. Chest 1989; 95:779–784.
   Google Scholar
• Kent-Braun JA, Sharma KR, Weiner MW, Massie B, Miller RG. Central basis of muscle fatigue in chronic fatigue syndrome. Neurology 1993; 43:125–131.
   Google Scholar
• Plioplys AV, Plioplys S. Serum levels of carnitine in chronic fatigue syndrome: clinical correlates. Neuropsychobiology 1995; 32:132–138.
   PubMed Web of Science ®Google Scholar
• Sisto SA, LaManca J, Cordero DL, Bergen MT, Ellis SP, Drastal S, Boda WL, Tapp WN, Natelson BH. Metabolic and cardiovascular effects of a progressive exer-cise test in patients with chronic fatigue syndrome. Am J Med 1996; 100:634–640.
   Google Scholar
• Borman P, Celiker R, Hascelik Z. Muscle performance in fibromyalgia syn-drome. Rheumatol Int 1999; 19:27–30.
   PubMed Web of Science ®Google Scholar
• Hakkinen A, Hakkinen K, Hannonen P, Alen M. Force production capacity and acute neuromuscular responses to fatiguing loading in women with fibromyalgia are not different from those of healthy women. J Rheuamtol 2000; 27:1277–1282.
   PubMed Web of Science ®Google Scholar
• McCully KK, Natelson BH. Impaired oxygen delivery to muscle in chronic fa-tigue syndrome. Clin Sci (Lond) 1999; 97:603–608; discussion 611-613.
   PubMed Web of Science ®Google Scholar
• Salerno A, Thomas E, Olive P, Blotman F, Picot MC, Georgesco M. Motor cor-tical dysfunction disclosed by single and double magnetic stimulation in patients with fibromyalgia. Clin Neurophysiol 2000; 111:994–1001.
   PubMed Web of Science ®Google Scholar
• Brickman AL, Fins Al. Psychological and cognitive aspects of chronic fatigue syndrome. In Goodnick Pt and Klimas N, Eds. Chronic Fatigue, and Related Immune Deficiency Syndromes. Washington and London: APPI 1993; 67–94.
   Google Scholar
• Sandman CA, Barron IL, Nackoul K, Goldstein J, Fidler F. Memory deficits as-sociated with chronic fatigue immune dysfunction syndrome. Biol Psychiatry 1993; 33:618–623.
   Google Scholar
• Marshall PS, Watson D, Steinberg P, Cornblatt B, Peterson PK, Callies A, et al. An assessment of cognitive function and mood in chronic fatigue syndrome. Biol Psy-chiatry 1996; 39:199–206.
   PubMed Web of Science ®Google Scholar
• Marshall PS, Forstot M, Callies A, Peterson PK, Schenck CH. Cognitive slow-ing and working memory difficulties in chronic fatigue syndrome. Psychosom Med 1997; 59:58–66.
   Google Scholar
• Gordon R, Michalewski HJ, Nguyen T, Gupta S, Starr A. Cortical motor poten-tial alterations in chronic fatigue syndrome. Int J Molec Med 1999; 4:493–499.
   Google Scholar
• Grace GM, Nielson WR, Hopkins M, Berg MA. Concentration and memory deficits in patients with fibromyalgia syndrome. J Clin Exp Neuropsychology 1999; 21:477–487.
   PubMed Web of Science ®Google Scholar
• Goodwin FK, Jamison KR. Manic-Depressive Illness. New York and Oxford: Oxford University Press; 1990.
   Google Scholar
• Emerson DC, Insel TR, Reus VI, Kopin IJ. Increased MHPG in dexamethasone-resistant depressed patients. Arch Gen Psychiatry 1983; 40:173–176.
   PubMed Web of Science ®Google Scholar
• Demitrack MA, Gold PW, Dale JK, Krahn DD, Kling MA, Straus SE. Plasma and cerebrospinal fluid monoamine metabolism in patients with chronic fatigue syn-drome: preliminary findings. Biol Psychiatry 1992; 32:1065–1077.
   PubMed Web of Science ®Google Scholar
• Sarrias MJ, Martinez E, Celada P, et al. Plasma free 5HT and platelet 5HT in de-pression: Case-controlled studies and the effect of antidepressant therapy. In: Schwarcz R, Ed. Kynurenine and Serotonin Pathways. New York, New York: Plenum Press; 1991:653–658.
   Google Scholar
• Ellis PM, Salmond C. Is platelet imipramine binding reduced in depression? A meta-analysis. Biol Psychiatry 1994; 36:292–299.
   PubMed Web of Science ®Google Scholar
• Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Javors MA, Bowden CA. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1992; 19:104–109.
   PubMed Web of Science ®Google Scholar
• Kravitz HM, Katz R, Kot E, Helmke N, Fawcett J. Biochemical clues to a fibromyalgia- depression link: Imipramine binding in patients with fibromyalgia or de-pression and in healthy controls. J Rheumatol 1992; 19:1428–1432.
   Google Scholar
• Cleare AJ, Beam J, Allain T, Mc Gregor A, Wessely S, Murray RM, O'Keane V. Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. J Affect Disord 1995; 34:283–289.
   Google Scholar
• Emberg M, Lundeberg T, Kopp S. Pain and allodynia/hyperalgesia induced by intramuscular injection of serotonin in patients with fibromyalgia and healthy individ-uals. Pain 2000; 85:31–39.
   Google Scholar
• Bondy B, Spaeth M, Offenbaecher M, Glatzeder K, Stratz T, Schwarz M, et al. The T102C polymorphism of the 5-HT2a receptor gene in fibromyalgia. Neurobiology Dis 1999; 6:433–439.
   PubMed Web of Science ®Google Scholar
• Klein R, Bansch M, Berg PA. Clinical relevance of antibodies against serotonin and gangliosides in patients with primary fibromyalgia syndrome. Psychoneuroendo-crinology 1992; 17:593–598.
   Google Scholar
• Klein R, Berg PA. A comparative study on antibodies to nucleoli and 5- hydro-xytryptamine in patients with fibromyalgia syndrome and tryptophan-induced eosino-philia-myalgia syndrome. Clin Investig 1994; 72:541–549.
   PubMedGoogle Scholar
• Korszun A, Sackett-Lundeen L, Papadopoulos E, et al. Melatonin levels in women with fibromyalgia and chronic fatigue syndrome. J Rheumatol 1999; 26:2675–2680.
   PubMed Web of Science ®Google Scholar
• Citera G, Arias MA, Maldonado-Cocco JA, Lazar° MA, Rosemffet MG, Brusco LI, ScheMes EJ, Cardinalli DP. The effect of melatonin in patients with fibromyalgia: A pilot study. Clin Rheumatol 2000; 19:9–13.
   Google Scholar
• Giovengo SL, Russell IJ, Larson AA. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rhematol 1999; 26:1564–1569.
   Google Scholar
• Evengard B, Nilsson CG, Lindh G, Lindquist L, Eneroth P, Fredrikson S, et al. Chronic fatigue syndrome differs from fibromyalgia. No evidence for elevated sub-stance P in cerebrospinal fluid of patients with chronic fatigue syndrome. Pain 1998; 78(2):153–155.
   Google Scholar
• Stratz T, Fiebich B, Haus U, Muller W. Influence of tropisetron on the serum substance P levels in fibromyalgia patients. Scand J Rheumatol Suppl 2004; 119:41–43.
   PubMedGoogle Scholar
• Brooks JC, Roberts N, Whitehouse G, Majeed T. Proton magnetic resonance spectroscopy and morphometry of the hippocampus in chronic fatigue syndrome. Br J Radiol 2000; 73 (875): 1206–1208.
   PubMed Web of Science ®Google Scholar
• Demitrack MA. Neuroendocrine research strategies in chronic fatigue syn-drome. In Goodnick PJ, Klimas N (Eds.), Chronic Fatigue and Related Immune Defi-ciency Syndromes. Washington and London: APPI 1993:45–66.
   Google Scholar
• Cleare AJ, Blair D, Chambers S, Wessely S. Urinary free cortisol in chronic fa-tigue syndrome. Am J Psychiatry 2001; 158:641–643.
   PubMed Web of Science ®Google Scholar
• Scott LV, Dinan TG. The neuroendocrinology of chronic fatigue syndrome: Fo-cus on the hypothalamic-pituitary-adrenal axis. Funct Neurol 1999; 14:3–11.
   PubMed Web of Science ®Google Scholar
• Scott LV, Dinan TG. Urinary free cortisol excretion in chronic fatigue syn-drome, major depression, and in healthy volunteer. J Affect Dis 1998; 47:49–54.
   PubMed Web of Science ®Google Scholar
• Scott LV, Salahuddin F, Cooney J, Svec F, Dinan TG. Differences in adrenal steroid profile in chronic fatigue syndrome, in depression, and in health. J Affect Dis 1999; 54:129–137.
   Google Scholar
• De Becker P, De Meirleir K, Joos E, Campine I, Van Steenberge E, Smitz J, Velkeniers B. Dehydroepiandrosterone (DHEA) response to iv ACTH in patients with chronic fatigue syndrome. Horm Metab Res 1999; 31:18–21.
   PubMed Web of Science ®Google Scholar
• Scott LV, Medbak S, Dinan TG. The low dose ACTH test in chronic fatigue syndrome and in health. Clin Endocrinol (Oxf) 1998; 48:733–737.
   PubMed Web of Science ®Google Scholar
• Scott LV, Medbak S, Dinan TG. Blunted adrenocorticotropin and cortisol re-sponses to corticotropin-releasing hormone stimulation in chronic fatigue syndrome. Acta Psychiatr Scand 1998; 97:450–457.
   Google Scholar
• Adler GK, Kinsley BT, Hurwitz S, Mossey CJ, Goldenberg DL. Reduced hypo-thalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Am J Med 1999; 106:534–543.
   Google Scholar
• Leal-Cerro A, Povedano J, Astorga R, Gonzalez M, Silva H, Garcia-Pesquera F, Casanueva FF, Dieguez C. The growth hormone (GH)-releasing hormone-GH-insu-lin-like growth factor-1 axis in patients with fibromyalgia syndrome. J Clin Endocrinol Metab 1999; 84:3378–3381.
   Google Scholar
• Cleare AJ, Sookdeo SS, Jones J, O'Keane V, Miell JP. Integrity of the growth hormone/insulin-like growth factor system is maintained in patients with chronic fa-tigue syndrome. J Clin Endocrinol Metab 2000; 85:1433–1439.
   Google Scholar
• Stewart TM, Gewitz MH, Weldon A, Arlievsky N, Li K, Munoz J. Orthostatic intolerance in adolescent chronic fatigue syndrome. Pediatrics 1999; 103:116–121.
   PubMed Web of Science ®Google Scholar
• Schondorf R, Benoit J, Wein T, Phaneuf D. Orthostatic intolerance in the chronic fatigue syndrome. J Auto Nerv Sys 1999; 75:192–201.
   PubMedGoogle Scholar
• LaManca JJ, Peckerman A, Walker J, Kesil W, Cook S, Taylor A, et al. Cardio-vascular response during head-up tilt in chronic fatigue syndrome. Clin Physiol 1999; 19:111–120.
   PubMedGoogle Scholar
• Ozgocmen S, Yoldas T, Kamanli A, Yildizhan H, Yigiter R, Ardicoglu 0. Au-ditory P300 event related potentials and serotonin reuptake inhibitor treatment in pa-tients with fibromyalgia. Ann Rheum Dis 2003; 62:551–555.
   Google Scholar
• Alanoglu E, Ulas UH, Ozdag F, Odabasi Z, Cakci A, Vural 0. Auditory event-related brain potentials in fibromyalgia. Rheumatol Int 2005; 25(5):345–349.
   Google Scholar
• Scheffers MK, Johnson R Jr, Grafman J, Dale JK, Strauss SE. Attention and short-term memory in chronic fatigue syndrome patients: an event-related potential analysis. Neurology 1992; 42(9):1667–1675.
   PubMed Web of Science ®Google Scholar
• Polich J, Moore AP, Wiederhold MD. P300 assessment of chronic fatigue syn-drome. J Clin Neurophysiol 1995; 12:186–191.
   Google Scholar
• George MS, Ketter TA, Post RM. SPECT and PET imaging in mood disorders. J Clin Psychiatry 1993; 54\(suppl 11):6–13.
   Google Scholar
• Goldstein JA. Chronic Fatigue Syndromes: The Limbic Hypothesis. New York, London, and Norwood, Australia: Haworth Medical Press; 1993.
   Google Scholar
• Machale SM, Lawrie SM, Cavanagh JT, Glabus MF, Murray CL, Goodwin GM, Ebmeier KP. Cerebral perfusion in chronic fatigue syndrome and depression. Br J Psychiatry 2000; 176:550–556.
   Google Scholar
• Costa DC, Tannock C, Brostoff J. Brainstem perfusion is impaired in chronic fatigue syndrome. QJM 1995; 88:767–773.
   Google Scholar
• Schwartz RB, Komaroff AL, Garada BM, Gleit M, Doolittle TH, Bates DW, et al. SPECT imagining of the brain: Comparison of findings in patients with chronic fatigue syndrome, AIDS dementia complex, and major unipolar depression. AJR Am J Roentgenol 1994; 162:943–951.
   PubMed Web of Science ®Google Scholar
• Cope H, Pernet A, Kendall B, David A. Cognitive functioning and magnetic resonance imaging in chronic fatigue. Br J Psychiatry 1995; 167:86–94.
   PubMed Web of Science ®Google Scholar
• Kwiatek R, Hamden L, Tedman R, Jarrett R, Chew J, Rowe C, Pile K. Regional cerebral blood flow in fibromyalgia: Single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. Arthritis Rheum 2000; 43:2823–2833.
   Google Scholar
• Lekander M, Frederikson M, Wik, G. Neuroimmune relations in patients with fibromyalgia: A positron emission tomography study, Neurosci Lett 2000; 282: 193–196.
   Google Scholar
• Stein M, Miller AH, Trestman RL. Depression, the immune system, and health and illness. Findings in search of meaning. Arch Gen Psychiatry 1991; 48:171–177.
   Google Scholar
• Lloyd AR, Wakefield D, Hickie I. Immunity and the pathophysiology of chronic fatigue syndrome. CIBA Found Symp 1993; 173:176–187; discussion 187-192.
   Google Scholar
• Barker E, Fujimura SF, Fadem MB, Landay AL, Levy JA. Immunologic abnor-malities associated with chronic fatigue syndrome. Clin Infect Dis 1994; 18\(suppl 1):S 136–S141.
   Google Scholar
• Nasralla M, Haier J, Nicolson GL. Multiple mycoplasmal infections detected in blood of patients with chronic fatigue syndrome and/or fibromyalgia syndrome. Eur J Clin Microbiol Infect Dis 1999; 18:859–865.
   Google Scholar
• Vernon SD, Shukla SK, Reeves WC. Absence of Mycoplasma species DNA in chronic fatigue syndrome. J Med Microbiol 2003; 52(Pt 11):1027–1028.
   PubMedGoogle Scholar
• Nijs J, Nicolson GL, De Becker P, Coomans D, De Meirleir K. High prevalence of Mycoplasma infections among European chronic fatigue syndrome patients. Exami-nation of four Mycoplasma species in blood of chronic fatigue syndrome patients. FEMS Immunol Med Microbiol 2002; 34(3):209–214.
   Google Scholar
• Jason LA, Taylor RR, Carrico AW. A community-based study of seasonal variation in the onset of chronic fatigue syndrome and idiopathic chronic fatigue. Chronobiol Int 2001; 18(2):315–319.
   Google Scholar
• Wallace HL 2nd, Natelson B, Gause W, Hay J. Human herpesviruses in chronic fatigue syndrome. Clin Diagn Lab Immunol 1999; 6:216–223.
   PubMedGoogle Scholar
• Koelle DM, Barcy S, Huang ML, Ashley RL, Corey L, Zeb J, Ashton S, Buchwald D. Markers of viral infection in monozygotic twins discordant for chronic fatigue syndrome. Clin Infect Dis 2002; 35(5):518–525.
   PubMed Web of Science ®Google Scholar
• Schutzer SE, Natelson BH. Absence of Borrelia burgdorferi-specific immune complexes in chronic fatigue syndrome. Neurology 1999; 53(6):1340–1341.
   PubMed Web of Science ®Google Scholar
• Gelman IH, Unger ER, Mawle AC, Nisenbaum R, Reeves WC. Chronic fatigue syndrome is not associated with expression of endogenous retroviral pl5E. Mol Diagn 2000; 5(2):155–156.
   Google Scholar
• Panerai AE, Vecchiet J, Panzeri P, Meroni P, Scarone S, Pizzigallo E, Giam-berardino MA, Sacerdote P. Peripheral blood mononuclear cell beta-endorphin con-centration is decreased in chronic fatigue syndrome and fibromyalgia but not in depression: preliminary report. Clin J Pain 2002; 18(4):270–273.
   Google Scholar
• Moss RB, Mercandetti A, Vojdani A. TNF-alpha and chronic fatigue syndrome. J Clin Immunol 1999; 19(5):314–316.
   Google Scholar
• Smirnova IV, Pall ML. Elevated levels of protein carbonyls in sera of chronic fatigue syndrome patients. Mol Cell Biochem 2003 Jun; 248(1-2):93–95.
   PubMed Web of Science ®Google Scholar
• Marcusson JA, Lindh G, Evengard B. Chronic fatigue syndrome and nickel al-lergy. Contact Dermatitis 1999; 40(5):269–272.
   Google Scholar
• Goodnick PJ, Sandoval R. Treatment of chronic fatigue syndrome and related disorders: immunological approaches. In Goodnick PJ, Klimas N, (Eds.) Chronic Fa-tigue and Related Immune Deficiency Disorders. Washington and London: APPI; 1993:108–129.
   Google Scholar
• Straus SE, Dale JK, Tobi M, Lawley T, Preble O, Blaese RM, et al. Acyclovir treatment of the chronic fatigue syndrome. Lack of efficacy in a placebo-controlled trial. N Engl J Med 1988; 319(26):1692–1698.
   Google Scholar
• Dubois RE. Gamma globulin therapy for chronic mononucleosis syndrome. AIDS Res Hum Retroviruses 1986; 2:S191–S195.
   Google Scholar
• Peterson PK, Shepard J, Macres M, Schenck C, Crosson J, Rechtman D, et al. A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome. Am J Med 1990; 89:554–560.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Hickie I, Wakefield D, Boughton C, Dwyer J. A double-blind, pla-cebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome. Am J Med 1990; 89:561–568.
   Google Scholar
• Behan PO, Behan WMH, Horrobin D. Effect of high doses of essential fatty ac-ids on the postviral fatigue syndrome. Acta Neurol Scand 1990; 82:209–216.
   PubMed Web of Science ®Google Scholar
• Sklar SH. Old drug with new application being tested as CEBV remedy. Chronic Fatigue Immune Deficiency Syndrome 1988; Winter/Spring:6–7.
   Google Scholar
• Peterson DL, Strayer DR, Bastein S, et al. Clinical improvements obtained with Ampligen in patients with severe chronic fatigue syndrome and associated encephalo-pathy. In Hyde B, Ed. The Clinical and Scientific Basis of Myalgic Encephalitis/Chronic Fatigue Syndrome. Ottawa: Nightingale Research Foundation; 1992; 634–638.
   Google Scholar
• Strayer DR, Carter WA, Brodsky I, Cheney P, Peterson D, Salvato P, et al. A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome. Clin Infect Dis 1994; 18\(suppl 1):588–595.
   Google Scholar
• Kaslow JE, Rucker L, Onishi R. Liver extract-folic acid-cyanocobalamin vs. placebo for chronic fatigue syndrome. Arch Inter Med 1989; 149:2501–2503.
   Google Scholar
• Steinbach TL, Hermann WJ Jr. The treatment of CFlDS with kutapressin. Chronic Fatigue Immune Dysfunction Syndrome 1990; Spring/Summer:25–30.
   Google Scholar
• Ericsson AD. Oral Alpha Interferon: Clinical Studies of Neuromuscular Dis-ease. Orange, California: G & S; 1991.
   Google Scholar
• Zachrisson 0, Colque-Navarro P, Gottfries CG, Regland B, Mollby R. Immune modulation with a staphylococcal preparation in fibromyalgia/chronic fatigue syn-drome: Relation between antibody levels and clinical improvement. Eur J Clin Micro-biol Infect Dis 2004; 23(2):98–105.
   Google Scholar
• Plioplys AV, Plioplys S. Amantidine and L-camitine treatment of Chronic Fa-tigue Syndrome. Neuropsychobiology 1997; 35:16–23.
   PubMed Web of Science ®Google Scholar
• Vermeulen RC, Scholte HR. Exploratory open label, randomized study of acetyl- and propionylcamitine in chronic fatigue syndrome. Psychosom Med 2004; 66(2):276–282.
   PubMed Web of Science ®Google Scholar
• McKenzie R, O'Fallon A, Dale J, Demitrack M, Sharma G, Deloria M, et al. Low-dose hydrocortisone for treatment of chronic fatigue syndrome: A randomized controlled trial. JAMA 1998; 280:1061–1066.
   PubMed Web of Science ®Google Scholar
• Cleare AJ, Heap E, Malhi GS, Wessely S, O'Keane V, Miell J. Low-dose hy-drocortisone in chronic fatigue syndrome: A randomised crossover trial. Lancet 1999; 353:455–458.
   Google Scholar
• Blockmans D, Persoons P, Van Houdenhove B, Lejeune M, Bobbaers H. Com-bination therapy with hydrocortisone and fludrocortisone does not improve symptoms in chronic fatigue syndrome: A randomized, placebo-controlled, double-blind, cross-over study. Am J Med 2003; 114(9):736–741.
   Google Scholar
• Scharf MB, Hauck M, Stover R, McDonnald M, Berkowitz D. Effect of gamma-hydroxybutyrate on pain, fatigue, and the alpha sleep anomaly in patients with fibromyalgia. J Rheumatol 1998; 25:1986–1990.
   Google Scholar
• Forsyth LM, Preuss HG, MacDowell AL, Chiazze L Jr., Birkmayer GD, Bellanti JA. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Ann Allergy Asthma Immunol 1999; 82:185–191.
   Google Scholar
• Warren G, McKendrick M, Peet M. The role of essential fatty acids in chronic fatigue syndrome. A case-controlled study of red-cell membrane essential fatty acids (EFA) and a placebo-controlled treatment study with high dose of EFA. Acta Neurol Scand 1999; 99:112–116.
   Google Scholar
• Puri BK, Holmes J, Hamilton G. Eicosapentaenoic acid-rich essential fatty acid supplementation in chronic fatigue syndrome associated with symptom remission and structural brain changes. Int J Clin Pract 2004; 58(3):297–299.
   Google Scholar
• Lange G, Holodny AT, DeLuca J, Lee HJ, Yan XH, Steffener J, Natelson BH. Quantitative assessment of cerebral ventricular volumes in chronic fatigue syndrome. Appl Neuropsychol 2001; 8:23–30.
   Google Scholar
• Bou-Holaigah I, Rowe PC, Kan, Calkins H. The relationship between neurally mediated hypotension and the chronic fatigue syndrome. JAMA 1995; 274:961–967.
   Google Scholar
• Rowe PC, Calkins H, DeBusk K, McKenzie R, Anand R, Sharma G, et al. Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syn-drome: A randomized controlled trial. JAMA 2001; 285:52–59.
   PubMed Web of Science ®Google Scholar
• Goodnick PJ, Sandoval R. Psychotropic treatment of chronic fatigue syndrome and related disorders. J Clin Psychiatry 1993; 54:13–20.
   PubMed Web of Science ®Google Scholar
• Wysenbeek J, Mor F, Lurie Y, Weinberg A. Imipramine for the treatment of fi-brositis: A therapeutic trial. Ann Rheum Dis 1985; 44:752–753.
   PubMed Web of Science ®Google Scholar
• Carette S, McCain GA, Bell DA, Fam AG. Evaluation of amitriptyline in pri-mary fibrositis. A double-blind, placebo-controlled study. Arthritis Rheum 1986; 29:655–659.
   PubMed Web of Science ®Google Scholar
• Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patient with fibromyalgia. Arthritis Rheum 1986; 29:1371–1377.
   PubMed Web of Science ®Google Scholar
• Scudds RA, McCain GA, Rollman GB, Harth M. Improvements in pain respon-siveness in patients with fibrositis after successful treatment with amitriptyline. J Rheumatol Suppl. 1989; 19:98–103.
   PubMedGoogle Scholar
• Gur A, Karakoc M, Nas K, Cevik R, Sarac J, Ataoglu S. Effects of low power la-ser and low dose amitriptyline therapy on clinical symptoms and quality of life in fibromyalgia: A single-blind, placebo-controlled trial. Rheumatol Int 2002; 22:188–193.
   PubMed Web of Science ®Google Scholar
• Fors EA, Sexton H, Gotestam KG. The effect of guided imagery and amitrip-tyline on daily fibromyalgia pain: A prospective, randomized, controlled trial. J Psychiatr Res 2002; 36:179–187.
   Google Scholar
• Gracious B, Wisner KL. Nortriptyline in chronic fatigue syndrome: A dou-ble-blind, placebo-controlled single case study. Biol Psychiatry 1991; 30:405–408.
   PubMed Web of Science ®Google Scholar
• Bibolotto E, Borghi C, Paculli E, et al. The management of fibrositis: A dou-ble-blind comparison of maprotiline, clomipramine, and placebo. Clinical Trials Jour-nal 1986; 23:269–280.
   Web of Science ®Google Scholar
• O'Malley PG, Jackson IL, Santoro J, Tomkins G, Balden E, Kroenke K. Anti-depressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 1999; 48:980–990.
   PubMed Web of Science ®Google Scholar
• Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 2000; 41:104–113.
   PubMed Web of Science ®Google Scholar
• Gantz NM, Holmes GP. Treatment of patients with chronic fatigue syndrome. Drugs 1989; 38:855–862.
   PubMed Web of Science ®Google Scholar
• Natelson BH, Cheu J, Pareja J, Ellis SP, Policastro T, Findley TW. Random-ized, double-blind, controlled placebo-phase in trial of low dose phenelzine in the chronic fatigue syndrome. Psychopharmacology (Berl.) 1996; 124:226–230.
   PubMed Web of Science ®Google Scholar
• Natelson BH, Cheu J, Hill N, Bergen M, Korn L, Denny T, Dahl K. Sin-gle-blind, placebo phase-in trial of two escalating doses of selegiline in the chronic fa-tigue syndrome. Neuropsychobiology 1998; 37:150–154.
   Google Scholar
• Hickie IB, Wilson AJ, Wright TM, Bennett BK, Wakefield D, Lloyd AR. A randomized, double-blind placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome. J Clin Psychiatry 2000; 61:643–648.
   PubMed Web of Science ®Google Scholar
• Goodnick PJ. Bupropion in chronic fatigue syndrome. Am J Psychiatry 1990; 147:1091.
   PubMed Web of Science ®Google Scholar
• Goodnick PJ, Sandoval R, Brickman AL, Klimas NG. Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome. Biol Psychiatry 1992; 32:834–838.
   PubMed Web of Science ®Google Scholar
• Geller SA. Treatment of fibrositis with fluoxetine hydrochloride (Prozac). Am J Med 1989; 87:594–595.
   PubMed Web of Science ®Google Scholar
• Finestone DH, Ober SK. Fluoxetine and fibromyalgia. JAMA 1990; 264:2869–2870.
   PubMed Web of Science ®Google Scholar
• Klimas NG, Morgan R, Van Riel F, et al. Observations regarding use of an anti-depressant fluoxetine in chronic fatigue syndrome. In Goodnick PJ, Klimas NG, (Eds.) Chronic Fatigue and Related Immune Deficiency Disorders. Washington and London: APPI; 1993:85–108.
   Google Scholar
• Lynch S, Seth R, Montgomery S. Antidepressant therapy in the chronic fatigue syndrome. Br J Gen Pract 1991; 41:339–342.
   Google Scholar
• Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994; 23:255–259.
   PubMed Web of Science ®Google Scholar
• Vercoulen JH, Swanink CM, Zitman FG, Vreden SG, Hoofs MP, Fennis JF, et al. Randomized, double-blind, placebo-controlled study of fluoxetine in chronic fa-tigue syndrome. Lancet 1996; 347:858–861.
   PubMed Web of Science ®Google Scholar
• Wearden AJ, Morriss RK, Mullis R, Strickland PL, Pearson DJ, Appleby L, Campbell IT, Morris JA. Randomised, double-blind, placebo-controlled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome. Br J Psychiatry 1998; 172:485–490.
   PubMed Web of Science ®Google Scholar
• Giordano N, Geraci S, Santacroce C, Mattii G, Battisti E, Gennari C. Efficacy and tolerability of paroxetine in patients with fibromyalgia syndrome: A single-blind study. Curr Ther Res 1999; 60(12):696–702.
   Web of Science ®Google Scholar
• Syuertsen JO, Smedsruk T, Lane RM. An open study of sertraline in fibro-myalgia syndrome. Eur Neuropsychopharmacol 1995; 5:315.
   Google Scholar
• Behan PO, Haniffah BAG, Doogan DP, Loudon M. A pilot study of sertraline for the treatment of chronic fatigue syndrome. Clin Infect Dis 1994; 18\(suppl 1): S111–112.
   Google Scholar
• Norregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995; 61:445–449.
   Google Scholar
• Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia-a randomized, double-blind, placebo-controlled study. Eur J Pain 2000; 4:27–35.
   Google Scholar
• Nishikai M, Akiya K. Fluvoxamine therapy for fibromyalgia. J Rheumatol 2003; 30(5):1124–1125.
   PubMed Web of Science ®Google Scholar
• Goodnick PJ. Treatment of chronic fatigue syndrome with venlafaxine. Am J Psychiatry 1996; 153(2):294.
   PubMed Web of Science ®Google Scholar
• Dwight MM, Arnold LM, O'Brien H, Metzger R, Morris-Park E, Keck, PE Jr. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics 1998; 39(1):14–17.
   Google Scholar
• Dyson E. Venlafaxine and fibromyalgia. N Z Med J 2000; 113:87.
   Google Scholar
• Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother 2003; 37( 11): 1561–1565.
   PubMed Web of Science ®Google Scholar
• Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ. A double-blind, multicenter trial comparing duloxetine with placebo in the treat-ment of fibromyalgia with or without major depressive disorder. Arthritis Rheum 2004; 50(9):2974–2984.
   Google Scholar
• Arnold LM, Rosen A, Pritchett YL, D' Souza DN, Goldstein DJ, Iyengar S., Wernicke JF. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119(1–3):5-15.
   Google Scholar
• Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, Ribeiro S, Gracely RH, Williams DA, Mease PJ, McLean SA, Clauw DJ. Efficacy of milnacipran in patients with fibromyalgia. Journal of Rheumatology 2005; 32(10):1975–1985.
   PubMed Web of Science ®Google Scholar
• Goodnick PJ, Jorge CM. Treatment of chronic fatigue syndrome with nefazodone. Am J Psychiatry 1999; 156:797–798.
   PubMed Web of Science ®Google Scholar
• Hickie I. Nefazodone for patients with chronic fatigue syndrome. Aust N Z J Psychiatry 1999; 33:278–280.
   PubMed Web of Science ®Google Scholar
• Samborski W, Lezanska-Szpera M, Rybakowski JK. Open trial of mirtazapine in patients with fibromyalgia. Pharmacopsychiatry 2004; 37(4):168–170.
   PubMed Web of Science ®Google Scholar
• Papadopoulos IA, Georgiou PE, Katsimbri PP, Drosos AA. Treatment of fibromyalgia with tropisetron, a 5HT3 serotonin antagonist: a pilot study. Clin Rheumatol 2000; 19:6–8.
   PubMed Web of Science ®Google Scholar
• Tolk J, Kohnen R, Muller W. Intravenous treatment of fibromyalgia with the 5-HT3 receptor antagonist tropisetron in a rheumatological practice. Scand J Rheumatol Suppl 2004; 119:72–75.
   Google Scholar
• Russell IJ, Fletcher EM, Michalek JE, McBroom PC, Hester GG. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A dou-ble-blind, placebo-controlled study. Arthritis Rheum 1991; 34:552–560.
   Google Scholar
• Tavoni A, Vitali C, Bombardier S, Pasero G. Evaluation of S-adenosyl-methionine in primary fibromyalgia. A double-blind, crossover study. Am J Med 1987; 83(5A): 107–110.
   Google Scholar
• Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syn-drome. J Int Med Res 1990; 18:201–209.
   PubMed Web of Science ®Google Scholar
• Puttini PS, Caruso I. Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: A 90-day open study. J Int Med Res 1992; 20:182–189.
   PubMed Web of Science ®Google Scholar
• Tyber MA. Lithium carbonate augmentation therapy in fibromyalgia. CMAJ 1990; 143:902–904.
   PubMed Web of Science ®Google Scholar
• Masand PS, Tesar GE. Use of stimulants in the medically ill. Psychiatric Clinics of North America 1996; 19:515–547.
   PubMed Web of Science ®Google Scholar
• Gemer R. Systematic treatment approach to depression and treatment resistant depression. Psychiatric Annals 1983; 13:37–49.
   Web of Science ®Google Scholar
• Stoll AL, Pillay SS, Diamond L, et al. Methylphenidate augmentation of seroto-nin selective reuptake inhibitors: A case series. J Clin Psychiatry 1996; 57:72–76.
   PubMed Web of Science ®Google Scholar
• Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antide-pressant treatment in depression. J Clin Psychiatry 2000; 61:378–381.
   Google Scholar
• Disdier P, Genton P, Milandre C, Bernard PM, Millet Y. Fibrositis syndrome and narcolepsy. J Rheumatol 1993; 20:888–889.
   PubMed Web of Science ®Google Scholar
• Schaller JL, Behar D. Modafinil in fibromyalgia treatment. J Neuropsychiatry Clin Neurosci 2001; 13 (4):530–531.
   PubMed Web of Science ®Google Scholar
• Turkington D, Hedwat D, Rider I, Young AH. Recovery from chronic fatigue syndrome with modafinil. Hum Psychopharmacol 2004; 19(1):63–64.
   PubMed Web of Science ®Google Scholar
• Bobo WV, Hall WC. On chronic fatigue syndrome. Am J Psychiatry 2004; 161:1132–1133.
   PubMed Web of Science ®Google Scholar
• Randall DC, Cafferty FH, Shneerson JM, Smith IE, Llewelyn MD, File SE. Chronic treatment with modafinil may not be beneficial in patients with chronic fatigue syndrome. J Psychopharmacol 2005; 19(6):647–660.
   PubMed Web of Science ®Google Scholar
• Olson LG, Ambrogetti A, Sutherland DC. A pilot randomized controlled study of dexamphetamine in patients with chronic fatigue syndrome. Psychosomatics 2003; 44(1):38–43.
   Google Scholar
• Berigan T. The use of atomoxetine adjunctively in fibromyalgia syndrome. Can J Psychiatry 2004; 49(7):499–500.
   PubMed Web of Science ®Google Scholar
• Kiser RS, Cohen HM, Freedenfeld RN, Jewell C, Fuchs PN. Olanzapine for the treatment of fibromyalgia symptoms. J Pain Symptom Manage 2001; 22(2):704–708.
   PubMedGoogle Scholar
• Rico-Villademoros F, Hidalgo J, Dominguez I, Garcia-Leiva TM, Calandre EP. Atypical antipsychotics in the treatment of fibromyalgia: A case series with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29(1):161–164.
   Google Scholar
• Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, Young JP Jr., LaMoreaux LK, Martin SA, Sharma U. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis and Rheumatism 2005; 52(4):1264–1273.
   Google Scholar
• Huuhka MJ, Haanpaa ML, Leinonen EV. Electroconvulsive therapy in patients with depression and fibromyalgia. European Journal of Pain 2004; 8(4):371–376.
   Google Scholar
• Usui C, Doi N, Nishioka M, Komatsu H, Yamamoto R, Ohkubo T, Ishizuka T, Shibata N, Hatta K, Miyazaki H, Nishioka K, Arai H. Electroconvulsive therapy im-proves severe pain associated with fibromyalgia. Pain 2006; 121(3):276–280.
   PubMed Web of Science ®Google Scholar
• Sampson SM, Rome JD, Rummans TA. Slow-frequency rTMS reduces fibromyalgia pain. Pain Medicine 2006; 7(2):115–118.
   Google Scholar
• Saletu B, Grunberger J. Drug profiling by computed electroencephalography and brain maps, with special consideration of sertraline and its psychometric effects. J Clin Psychiatry 1988; 49(8) Supp1:59–71.
   Google Scholar
• Doraiswamy PM, Krishnan KR, Oxman T, Jenkyn LR, Coffey DJ, Burt T, Clary CM. Does antidepressant therapy improve cognition in elderly depressed pa-tients? J Gerontol A Biol Sci Med Sci 2003; 58(12):M1137–144.
   PubMedGoogle Scholar
• Riedel WJ, Eikmans K, Heldens A, Schmitt JA. Specific serotonergic reuptake inhibition impairs vigilance performance acutely and after subchronic treatment. J Psychopharmacol 2005; 19(1):12–20.
   PubMed Web of Science ®Google Scholar
• Wiebe E. N of 1 trials. Managing patients with chronic fatigue syndrome: Two case reports. Can Fam Physician 1996; 42:2214–2217.
   Google Scholar
• Chaudhuri A, Watson WS, Pearn J, Behan PO. The symptoms of chronic fa-tigue syndrome are related to abnormal ion channel function. Med Hypotheses 2000; 54(1):59–63.
   PubMed Web of Science ®Google Scholar
• Lawson K. Tricyclic antidepressants and fibromyalgia: What is the mechanism of action. Expert Opin Investig Drugs 2002; 11(10):1437–1445.
   PubMed Web of Science ®Google Scholar
• Mainero C, Inghilleri M, Pantano P, Conte A, Lenzi D, Frasca V, Bozzao L, Pozzilli C. Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine. Neurology 2004; 62(11):2044–2050.
   PubMed Web of Science ®Google Scholar